Pioneers cancer therapies that exploit oncogene overactivation to create targeted, resistance-fighting treatments.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer’s surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Investors
Alexandria Venture Investments
Google Ventures
Nextech Invest Ltd.
Polaris Partners
Delphia Therapeutics Valuations & Financials
View real-time NPM data on Delphia Therapeutics stock including daily Delphia Therapeutics stock price estimates, valuation history, and historical share price information. Access Delphia Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Delphia Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Delphia Therapeutics? Get in touch to learn more.
Similar Companies
like Delphia Therapeutics
Clipboard Health
Healthcare & Life Sciences
Uses technology to help nursing facilities get the right nurse at the right place at the right time.
Devoted Health
Healthcare & Life Sciences
Provides Medicare Advantage plans to improve older Americans' well-being with comprehensive and family-oriented care.
Capstan Medical
Healthcare & Life Sciences
Merges surgical robotics with catheter-based technology to repair and replace heart valves.
Loyal
Healthcare & Life Sciences
Develops therapies to treat the underlying causes of aging in dogs.
Q Bio
Healthcare & Life Sciences
Utilizes AI and continuous monitoring to provide personalized health insights for proactive well-being decisions.
Dragonfly Therapeutics
Healthcare & Life Sciences
Creates immune-based therapies designed to target and eliminate cancer cells.
FAQ
We have answers
Delphia Therapeutics stock does not trade on public stock exchanges. Delphia Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Delphia Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Delphia Therapeutics Stock does not trade on public stock exchanges. In order to sell Delphia Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Delphia Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Delphia Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Delphia Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Delphia Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Delphia Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Delphia Therapeutics is a private company and has not had an IPO. There is currently no Delphia Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Delphia Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
